MedTrace Logo

Hemodynamic, Laboratory, and Clinical Outcomes of Hemoadsorption Therapy

NCT07679555 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-07-07

No results posted yet for this study

Summary

This single-center retrospective observational cohort study aims to evaluate the clinical, hemodynamic, and laboratory effects of adjunctive hemoadsorption therapy in critically ill adult patients treated in the Intensive Care Unit of Flór Ferenc Hospital, Hungary, between January 1, 2020, and May 31, 2026. Patients who received CytoSorb® or Efferon LPS® hemoadsorption therapy will be included.

The study will assess changes in vasopressor requirements, hemodynamic parameters, inflammatory biomarkers, liver function tests, tissue perfusion markers, and oxygenation following hemoadsorption treatment. Clinical outcomes, including intensive care unit length of stay, all-cause mortality occurring during the patient's stay in the intensive care unit (ICU mortality), and 28-day and 90-day mortality, will also be evaluated. Data will be collected retrospectively from anonymized medical records, and no study-related interventions will be performed.

Conditions

  • Hemoadsorption
  • Vasopressor Therapy

Interventions

PROCEDURE

Hemoadsorption

Patients included in this retrospective observational study received adjunctive hemoadsorption therapy as part of routine clinical care at the discretion of the treating intensive care physicians. Hemoadsorption was performed using either the CytoSorb® or Efferon LPS® hemoadsorption cartridge, according to the clinical indication and device availability. Hemoadsorption was integrated into a continuous renal replacement therapy (CRRT) circuit. Treatment duration, number of hemoadsorption sessions, timing of therapy initiation, and concomitant intensive care interventions were determined by the treating physicians and were not influenced by the study protocol. No study-specific interventions, additional diagnostic procedures, or protocol-mandated treatments were performed.

Sponsors & Collaborators

  • Pest County Flór Ferenc Hospital

    lead OTHER

Principal Investigators

  • Zoltán Ruszkai, MD, PhD · Pest County Flór Ferenc Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2026-05-31
Completion
2026-09-30

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07679555 on ClinicalTrials.gov